Impact of Resveratrol and Pharmaceutical Care on Type 2 Diabetes Mellitus and Its Neuropathic Complication: A Randomized Placebo Controlled Clinical Trial

Table 5

The effect of resveratrol supplementation and pharmaceutical care versus placebo on neopterin levels in diabetic patients with neuropathic complications.

Time	Group
	Resv (n = 25)	Placebo (n = 23)	Resv + PC (n = 25)	Placebo + PC (n = 24)
Neopterin (nmol/L) day-0	4.657 ± 0.620	4.478 ± 0.668	4.630 ± 0.675	4.522 ± 0.853
Neopterin (nmol/L) day-90	4.511 ± 0.652	4.107 ± 0.648	4.399 ± 0.688	4.280 ± 0.564

Values are presented as mean ± SD; the data show that there are no significant differences in neopterin levels between resveratrol supplementation and pharmaceutical care versus placebo and pharmaceutical care on neopterin level after 90-day interventions ( value >0.05). Two-way ANOVA repeated measures analysis of variance (ANOVA) and multiple comparisons were performed and confirmed using Tukey’s test. n, number of patients; Resv, resveratrol; PC, pharmaceutical care.